BioRestorative Therapies (BRTX) announced a major intellectual property milestone: the Japanese Patent Office, JPO, has issued a Notice of Allowance for the Company’s ThermoStem platform. The newly allowed patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf brown adipose-derived stem cell technology, designed to treat obesity and metabolic disorders. These claims are materially stronger than previously granted patents, covering not only the therapeutic cells themselves, but also multiple methods of encapsulation and delivery – including alginate microcapsules, cellulose hydrogels, polymer membranes, and advanced scaffolding systems.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX: